Monthly Archives: April 2018

MIXiii-Biomed 2018: 2 Days Only to the Early Bird Registration Deadline

Dear Partners, MIXiii-BIOMED Israel 2018 promises to follow the tradition of successful events.This year’s program will consist of 9 tracks, each of them will host plenary and keynote speakers, a panel discussion and time dedicated to questions and answers, allowing an interactive atmosphere in each hall.Our MIXiii-Biomed Co-Chairs, together with the track Chairs, have gathered together an [...]

By |2018-11-20T09:36:52+00:00April 30th, 2018|News|Comments Off on MIXiii-Biomed 2018: 2 Days Only to the Early Bird Registration Deadline

Israeli Medical Device Developer V-Wave Raises $70 Million

V-Wave develops a minimally #invasive #implanted #shuntdevice for treating patients with severe #heartfailure Meir Orbach | 26.04.18 | CTech  Israeli #medical shunt #developer V-Wave Ltd. announced on Thursday it completed a $70 million series C financing round led by U.S. #investment firm Deerfield Management Company, L.P. with participation from medtech funds Endeavour Vision SA, Quark Venture [...]

By |2018-11-20T09:37:26+00:00April 29th, 2018|Blog|Comments Off on Israeli Medical Device Developer V-Wave Raises $70 Million

Eloxx Pharmaceuticals raises $50m on Nasdaq

News| Globes The company is developing a drug for treatment of cystic fibrosis. Eloxx Pharmaceuticals, which develops drugs for rare genetic diseases, announced that it has raised $50 million at $9.75 per share, 8% lower than yesterday's market price. The company will be listed on Nasdaq following its financing round. Eloxx, which merged a [...]

By |2018-11-20T09:38:23+00:00April 29th, 2018|Blog|Comments Off on Eloxx Pharmaceuticals raises $50m on Nasdaq

U.S. FDA Clears Pluristem’s Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery

Multinational study expected to include clinical sites in U.S. Israel and Europe, where study has been awarded an $8.7 million grant from European Horizon 2020 Program April 25, 2018 07:00 ET | HAIFA, Israel, April 25, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that the U.S. [...]

By |2018-11-20T09:38:11+00:00April 26th, 2018|Blog|Comments Off on U.S. FDA Clears Pluristem’s Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery

The Rise of #Nanomedicine

APRIL 18, 2018 | Research | NanoMagazine Medicine has been around for thousands of years, but as always, medicine is changing. Throughout the years, humans have switched from apothecary to packing active pharmaceutical ingredients (APIs) into #ingestibleDrugs, and now, #nanomedicine is developing into the medicine of the future. Here, we look at how nanomedicine is being [...]

By |2018-11-20T09:37:01+00:00April 25th, 2018|Blog|Comments Off on The Rise of #Nanomedicine

CytoReason uses AI to personalize #drugs, opening the door to #cancer treatments

STEWART ROGERS | APRIL 16, 2018 8:30 AM The first question most people have when talking about #artificialIntelligence is if it will help us or harm us. But in the health industry, the answer to that question is clear. Whether it is being used to identify patients at risk or interrogate #X-rays and scans to aid in diagnosis, AI promises to [...]

By |2018-11-20T09:48:01+00:00April 24th, 2018|Blog|Comments Off on CytoReason uses AI to personalize #drugs, opening the door to #cancer treatments

Spotlight On Israel: Market Challenges Stunting Biopharma Growth

23 Apr 2018 | Lucie Ellis Executive Summary Scrip investigates the big issues Israel's #biopharma sector need to overcome in order to maintain momentum and achieve sustainable success. AHARON AHARON, CEO OF THE ISRAEL INNOVATION AUTHORITY. Source: Israel Innovation Authority In its 70th anniversary year, Israel can rightly celebrate the boom in its high-tech sector over the last [...]

By |2018-11-20T09:48:32+00:00April 24th, 2018|Blog, PR|Comments Off on Spotlight On Israel: Market Challenges Stunting Biopharma Growth

MIXiii-Biomed 2018 Early Bird Registration – one week left

1 (ONE) Week to Go… Early Bird Registration Deadline Israel remains one of the superpowers in the field of Nanotechnology, with far-reaching effects into many diverse industries, one of which is Biomedicine.  MIXiii-Biomed 2018 is ready to welcome thousands of participants from Israel and around the globe. This year, we are proud to announce, a [...]

By |2018-04-24T11:26:06+00:00April 23rd, 2018|News|Comments Off on MIXiii-Biomed 2018 Early Bird Registration – one week left

(Personalized medicine is approaching a major breakthrough” (Hebrew”

"הרפואה המותאמת אישית מתקרבת לפריצת דרך משמעותית" פרופ' דיוויד סידרנסקי, חוקר סרטן נודע בארה"ב ומנהל קרן השקעות הביומד בישראל (IBF), מסביר בראיון ל"גלובס" מדוע רק עכשיו הרפואה המותאמת אישית עומדת להצדיק את ההייפ שהיה סביבה לפני עשור ● סידרנסקי מגלה גם שחברת איילה פארמה, מהחברות המובילות בפורטפוליו, מתכננת הנפקה, ומפרט את מטרות הקרן: "אנחנו מחפשים [...]

By |2018-11-20T09:32:11+00:00April 17th, 2018|News|Comments Off on (Personalized medicine is approaching a major breakthrough” (Hebrew”

MIXiii-Biomed 2018 – Meet the Start-ups

  A world of medical innovations MEET THE START-UPS The annual 17th MIXiii-Biomed Exhibition and Conference will open its doors on 15 May 2018. Every year MIXiii-Biomed introduces to its participants start-up companies bringing the latest innovations in technology and science and will, without any doubt, help shape the future of the BIOMED industry. This year is no [...]

By |2018-04-17T08:25:28+00:00April 16th, 2018|News|Comments Off on MIXiii-Biomed 2018 – Meet the Start-ups